Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 15/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24244801 | 0.84 | MEN1 (0.48) | ADRA1AALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL11890311 | 0.82 | ALDH1A1 (0.65) | ALDH1A1LMNAMEN1KMT2APOLB | |
| SCHEMBL22891321 | 0.81 | DPP4 (0.41) | ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL26148290 | 0.81 | DPP4 (0.41) | ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL19652192 | 0.81 | ADRA1A (0.47) | ADRA1AALDH1A1LMNA | |
| SCHEMBL19658401 | 0.79 | ADRA1A (0.50) | ADRA1AALDH1A1LMNA | |
| SCHEMBL31482179 | 0.79 | ADRA1A (0.50) | ADRA1AALDH1A1LMNA | |
| SCHEMBL20692579 | 0.78 | ALDH1A1 (0.50) | ALDH1A1LMNAMEN1KMT2APOLB | |
| SCHEMBL9921669 | 0.78 | ALDH1A1 (0.50) | ALDH1A1LMNAMEN1KMT2APOLB | |
| SCHEMBL9921671 | 0.78 | ALDH1A1 (0.50) | ALDH1A1LMNAMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210179626-A1 | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20200165260-A1 | INHALED POWDER FORMULATIONS | GENENTECH, INC. (US) | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179626-A1 | PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | JAK1, JAK2, JAK3 | ADRA1A 4846/4885ALDH1A1 1102/4885LMNA 4129/4885 |
| US-20200165260-A1 | INHALED POWDER FORMULATIONS | JAK1, STAT5A, JAK2 | ADRA1A 27/4885ALDH1A1 2796/4885LMNA 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.